OVID

Over the past six months (April to October 2026), several events impacted Ovid Therapeutics' stock price: positive clinical data for OV329 and Phase 1 clearance for OV4071 were announced in March 2026, contributing to a significant stock surge. An earnings beat in Q4 2025, with an EPS of $0.06 against an expected -$0.10, fueled an initial rally. A $60 million private placement financing and potential additional funds from warrant exercises (up to $53.9 million) strengthened the company's cash position, extending its financial runway into 2029. OV329 demonstrated a favorable safety profile and is progressing to Phase 2 studies for treatment-resistant epilepsies and new pediatric programs, while OV4071 began Phase 1 dosing in Q2 2026. A newly formed company, backed by Perceptive Advisors, acquired global rights to soticlestat, with Ovid retaining equity and eligibility for potential milestone payments and royalties. The company announced CFO changes in July 2026 and strengthened its executive leadership team. Ovid initiated Phase 2 and photosensitivity proof-of-concept studies for OV329 after receiving regulatory clearances. In August 2026, new major and minor risks were identified concerning revenue and earnings growth, with forecasts indicating a decline in earnings and current revenue being less than US$5 million. September 2026 saw bearish stock trends, with OVID moving below its 50-day moving average on September 23, 2026, and the 10-day moving average crossing bearishly below the 50-day moving average on September 28, 2026, signaling a potential downward trend. In October 2026, positive topline results for OV329 were announced.